Endorphins are polypeptides made by the pituitary gland and central nervous system to moderate the production of neurotransmitters, such as serotonin and dopamine. Endorphins primarily help us to reduce pain and inflammation, promote autophagy, and cellular clean up. In individuals with diagnoses such as depression, fibromyalgia, cognitive degeneration, and autoimmunity, consistent findings show chronically low levels of endorphins—specifically, low levels of an endorphin called the Opioid Growth Factor (OGF). OGF is an endorphin produced in most cells in the body to both influence and regulate cell growth, as well as immunity. When low levels of OGF endorphins exist, it is likely for individuals to develop immune system disorders. Low Dose Naltrexone (LDN) has been shown to increase OGF levels in the body, resulting in positive outcomes for those suffering from the aforementioned diagnoses.
LDN first binds to opioid receptors. In doing so, it helps to displace the body’s naturally produced OGF. As LDN displaces OGF receptors, affected cells become OGF-deficient and, as a result, three vital processes occur: